DE69433921D1 - Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie - Google Patents

Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Info

Publication number
DE69433921D1
DE69433921D1 DE69433921T DE69433921T DE69433921D1 DE 69433921 D1 DE69433921 D1 DE 69433921D1 DE 69433921 T DE69433921 T DE 69433921T DE 69433921 T DE69433921 T DE 69433921T DE 69433921 D1 DE69433921 D1 DE 69433921D1
Authority
DE
Germany
Prior art keywords
cell line
gene therapy
recombinant cells
macrophage cell
monocyte macrophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433921T
Other languages
English (en)
Other versions
DE69433921T2 (de
Inventor
Hedi Haddada
Manuel Lopez
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTELION, VITRY SUR SEINE, FR
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Aventis Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE69433921D1 publication Critical patent/DE69433921D1/de
Publication of DE69433921T2 publication Critical patent/DE69433921T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69433921T 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie Expired - Fee Related DE69433921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9310222A FR2709309B1 (fr) 1993-08-25 1993-08-25 Compositions cellulaires, préparation et utilisations thérapeutiques.
FR9310222 1993-08-25
PCT/FR1994/001019 WO1995006120A1 (fr) 1993-08-25 1994-08-22 Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique

Publications (2)

Publication Number Publication Date
DE69433921D1 true DE69433921D1 (de) 2004-09-02
DE69433921T2 DE69433921T2 (de) 2006-10-05

Family

ID=9450378

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433921T Expired - Fee Related DE69433921T2 (de) 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Country Status (14)

Country Link
US (1) US6210963B1 (de)
EP (1) EP0719332B1 (de)
JP (1) JP3731035B2 (de)
KR (1) KR100392984B1 (de)
AT (1) ATE272117T1 (de)
AU (1) AU698043B2 (de)
CA (1) CA2170159A1 (de)
DE (1) DE69433921T2 (de)
FI (1) FI960855A (de)
FR (1) FR2709309B1 (de)
IL (1) IL110754A (de)
NO (1) NO319990B1 (de)
WO (1) WO1995006120A1 (de)
ZA (1) ZA946264B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
DE69732710T2 (de) * 1996-10-09 2005-07-28 Oxford Biomedica (Uk) Ltd. Mononukleare phagozyten zur verabreichung von therapeutischen arzneimitteln
US20020068048A1 (en) * 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
JP2001517453A (ja) * 1997-09-23 2001-10-09 オックスフォード バイオメディカ（ユーケイ）リミテッド 方 法
EP1165754A1 (de) * 1999-04-06 2002-01-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmazeutische zusammensetzung enthaltend zirkulierende blutzellen, bevorzugt monocyten, und deren verwendung
US20020034501A1 (en) * 2000-05-18 2002-03-21 Robert Pawliuk Methods and compositions for promoting angiogenesis using monocytes
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
AU2003203527A1 (en) * 2002-04-12 2003-10-30 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
MXPA05005921A (es) * 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
EP1638587A4 (de) 2003-02-14 2007-04-18 Univ Missouri Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
WO2005097988A1 (ja) * 2004-03-23 2005-10-20 Dnavec Research Inc. 組織の維持および／または修復に関連する骨髄関連細胞
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
BRPI0720342A2 (pt) * 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
US8202717B2 (en) 2007-01-12 2012-06-19 The Board Of Trustees Of The University Of Illinois Non-simian cells for growth of porcine reproductive and respiratory syndrome (PRRS) virus
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 ＲＮＡウイルスＢｍＭＬＶ陰性カイコ培養細胞株
EP2248903A1 (de) * 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
AU2014255733B2 (en) 2013-04-18 2019-05-16 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CN110709508A (zh) * 2017-03-28 2020-01-17 朱正仑 治疗新生性疾病的方法
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4240367A2 (de) 2020-11-04 2023-09-13 Myeloid Therapeutics, Inc. Manipulierte chimäre fusionsproteinzusammensetzungen und verfahren zur verwendung davon
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
EP0667792A1 (de) * 1991-11-22 1995-08-23 The General Hospital Corporation Spezifische toleranz bei transplantation
US5338165A (en) * 1991-11-25 1994-08-16 Ford Motor Company Automotive fuel pump with modular pump housing
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
US5436151A (en) * 1992-04-03 1995-07-25 Regents Of The University Of Minnesota Method for culturing human hematopoietic stem cells in vitro
DE4219626A1 (de) * 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
CA2158455C (en) * 1993-03-17 2003-05-27 Nicholas P. Restifo Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors

Also Published As

Publication number Publication date
JPH09501837A (ja) 1997-02-25
EP0719332A1 (de) 1996-07-03
NO960743L (no) 1996-03-25
WO1995006120A1 (fr) 1995-03-02
US6210963B1 (en) 2001-04-03
FI960855A0 (fi) 1996-02-23
CA2170159A1 (fr) 1995-03-02
FR2709309B1 (fr) 1995-11-10
IL110754A (en) 2001-04-30
NO319990B1 (no) 2005-10-10
FR2709309A1 (fr) 1995-03-03
IL110754A0 (en) 1994-11-11
DE69433921T2 (de) 2006-10-05
NO960743D0 (no) 1996-02-23
AU7539894A (en) 1995-03-21
ZA946264B (en) 1995-03-20
JP3731035B2 (ja) 2006-01-05
EP0719332B1 (de) 2004-07-28
AU698043B2 (en) 1998-10-22
KR100392984B1 (ko) 2004-10-20
ATE272117T1 (de) 2004-08-15
FI960855A (fi) 1996-04-23

Similar Documents

Publication Publication Date Title
DE69433921D1 (de) Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
MX9806064A (es) Composicion de enzimas para disociacion de tejidos.
DE69527540D1 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
ES2143620T3 (es) Polipeptidos modificados con actividad biologica incrementada.
BR9402832A (pt) Determinação de nódulos linfa enriquecidos em células reativas de tumor, sua proliferação e uso em terapia celular adotiva
DE69430059T2 (de) Freisetzung und Mobilisierung hämatopoietischer Zellen
ES8707483A1 (es) Un metodo para acilar derivados de naftaleno
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
AU2002304249A1 (en) Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
ES2144626T3 (es) Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si.
ATE144791T1 (de) Innerhalb des alpha-locus gelegenes t-zell- rezeptor-gen und dna-konstruktionen
ATE225183T1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
SE8605459D0 (sv) Novel cell growth regulatory factor
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
ATE137241T1 (de) Oligosaccharides
DE60115039D1 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität
ES2061057T3 (es) Proteccion de la actividad citolitica de celula nk en pbmc.
AU1402495A (en) Use of macrophage depleting agents for prolonging the survival of non-autologus hematopoietic cell transplants and animal model assay systems
GB8925435D0 (en) The production of lak cells,compositions containing them,and their use

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Owner name: CENTELION, VITRY SUR SEINE, FR

8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee